Solasto Corporation (6197.T)

Solasto Corporation (6197.T) — VMCI valuation read

Headline read on 6197.T: VMCI of 57/100 versus a Healthcare sector median of 50. The 7-point above-median position is what makes Solasto Corporation a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on 6197.T: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on 6197.T: value (6197.T trades at 19.0x earnings, 6% above the Healthcare median of 18.0x), quality (ROIC of 11.0% sits 1.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 2.7x is the rate-sensitivity line to watch). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

6197.T fell 1.8% over the trailing 7 days, with a +6.3% read on a 30-day basis.